Key facts
- In January 2026, 12 EU/EEA countries reported 173 measles cases. Sixteen countries reported zero cases.
- During the last 12-month period, six deaths attributable to measles were reported to ECDC by France (4), Romania (1) and the Netherlands (1).
- Overall, case numbers increased compared with previous months.
- Complementary epidemic intelligence surveillance was performed on 10 and 11 March 2026. An increase of cases has been detected in Madrid, Spain. Sporadic cases and clusters were reported in several EU/EEA countries. Updates are provided for several countries and regions outside the EU/EEA.
Overview
In January 2026, 28 EU/EEA countries reported measles data. Twelve countries reported 173 cases and 16 countries reported zero cases.
Overall, case numbers increased compared with the previous month, however this may be subject to change in the event of a future retrospective update. The highest case counts were reported by Italy (84), Spain (48), France (12), Romania (nine) and Belgium (seven).
Between 1 February 2025 and 31 January 2026, 30 EU/EEA countries reported a total of 6 037 cases of measles, 4 866 (80.6%) of which were laboratory confirmed.
Of the 6 037 cases with known age, 2 250 (37.3%) were in children aged under five years; and 2 282 (37.8%) cases were in those aged 15 years or above. The highest notification rates were observed in infants under one year of age (185.5 cases per million) and children aged 1-4 years (94.6 cases per million).
Of 5 736 individuals (95.0% of all cases) with a known age and vaccination status, 4 455 (77.7%) were unvaccinated, 638 (11.1%) were vaccinated with one dose of a measles-containing vaccine, 516 (9.0%) were vaccinated with two or more doses, and 117 (2.0%) were vaccinated with an unknown number of doses.
During the 12-month period, six deaths (case fatality rate (CFR): 0.099 %) attributable to measles were reported to ECDC by France (four), Netherlands (one) and Romania (one). Detailed data are available in ECDC's Surveillance Atlas of Infectious Diseases.
Complementary epidemic intelligence surveillance was performed on 10 and 11 March 2026. An increase of cases has been detected in Madrid, Spain. Sporadic cases and clusters were reported in several EU/EEA countries. Outside the EU/EEA, updates have been provided for Serbia, England, Northern Ireland, Israel, Ukraine, Australia, Africa CDC, Canada, US and the World Health Organization Pan American Health Organization (WHO PAHO) region.
Disclaimer: The monthly measles report published in the CDTR provides the most recent data on cases and outbreaks based on information made publicly available by the national public health authorities or the media. Sometimes this information is made available retrospectively. This report is a supplement to ECDC’s monthly measles and rubella monitoring report, based on data routinely submitted by 30 EU/EEA countries to EpiPulse Cases. Data presented in the two monthly reports may differ.
Epidemiological summary for EU/EEA countries with relevant epidemic intelligence updates:
Austria reported three cases in 2026 and as of 26 February, an increase by one case.
Estonia reported two new cases in January 2026 and as of 10 March 2026 and 11 cases in 2025.
Germany reported 38 confirmed and probable measles cases in 2026 (week 1 to 10), an increase of four cases from week 7. No outbreaks have been detected by ECDC EI group.
Hungary reported one case in 2026 and as of 10 March.
Ireland reported four cases in 2026 in weeks 1 to 8. Data from Ireland (National Notifiable Disease Hub) includes confirmed, probable, and possible measles cases.
Italy reported 84 new cases in January 2026 (73 laboratory confirmed, five probable and six possible cases) in January 2026 as of 19 February 2026. Of the reported cases, five were healthcare workers. Genotype D8 and B3 were detected in 15 and 6 samples, respectively.
Poland reported eight cases of measles from 1 January to 28 February 2026, an increase of 6 cases since end of January 2026.
Spain reported 81 cases of measles from 1 January to 1 March 2026, including three imported and six cases related to imported cases. This represents an increase of 49 cases since 8 February 2026.
According to media report on 11 March 2026, an increase of measles cases has been reported in Madrid. Between weeks 1 and 7 in 2026, Madrid reported 24 cases of measles involving several family clusters. The number of cases in Madrid is now exceeding the total number reported in the city in 2025.
Sweden reported three cases in 2026 and as of 10 March.
Epidemiological summary for EU/EEA outermost territories with relevant epidemic intelligence updates:
No new outbreaks or cases have been detected in the reporting period.
Western Balkan countries and Türkiye
Serbia reported 204 measles cases in 2025 and as of report in February 2026.
Epidemiological summary for selected countries outside of the EU/EEA with relevant epidemic intelligence updates:
England reported 195 laboratory confirmed cases between 1 January and 2 March 2026. Cases have increased in January 2026, mostly driven by the ongoing outbreak in North London. The majority of cases involve children under aged 10 years of age and under (73%).
Northern Ireland reported six suspected measles cases during January and February 2026, of those none were confirmed.
Ukraine reported 1 461 measles cases from January to December 2025.
Israel reported 372 measles cases in 2026 and as of 25 February 2026.
Australia reported 64 cases in 2026 and as of 11 March 2026.
Africa CDC reported on 9 March 2026, overall, in 2026, there have been reported 23 843 cases of measles (692 confirmed) and 238
deaths in eight countries: DRC (20 231 cases, 238 deaths), Guinea (71; 0), Liberia (46; 0), Mali (123;0) Mozambique (85; 0), Senegal (11; 0), Somalia (2 920; 0) and South Africa (356; 0). Mali is listed as a high risk to population and a moderate risk is indicated in Mozambique.
The US continues to face multiple concurrent outbreaks, including several that began in 2025 and continue into 2026. High transmission is concentrated in select states, with 89% of cases outbreak‑associated, indicating persistent chains of community transmission and pressure on elimination status. Overall US CDC reported 1 281 cases and no deaths as of national report on 6 March 2026.
Canada reported 339 measles cases (314 confirmed) and no deaths across seven jurisdictions in 2026 and as of 2 March 2026. The country remains in active transmission across multiple provinces.
Mexico reported on 10 March 2026, overall since the beginning of the outbreak in 2025, 12 963 confirmed cases were reported, including 34 deaths. In 2026, Mexico reported 6 511 confirmed cases and seven deaths. Mostly affected state is Jalisco (3 823 cases; two deaths).
According to WHO PAHO, in 2026 (week 1–6), 2 740 measles cases and no deaths were reported in the Americas Region. Cases were notified by Mexico (1 104), the United States (US) (970), Guatemala (374), Canada (254), Bolivia (34), Chile (1), Costa Rica (1), Peru (1), and Uruguay (2).
For more information on the provisional number of cases outside the EU/EEA region, please visit the World Health Organization (WHO) website.
The numbers provided to WHO for EU/EEA countries are from EpiPulse Cases data, which are updated monthly and available on the ECDC Surveillance Atlas of Infectious Diseases. Due to differences in reporting times, the numbers may not correspond to the data from epidemic intelligence screening.
ECDC assessment
Although most recent cases were acquired through local or community transmission, travel-related cases continue to be reported.
Continued vigilance is essential due to sub-optimal vaccination coverage for measles-containing vaccines (MCV) in several EU/EEA countries, possible introduction from areas with ongoing transmission, and increased travel and population movement during holiday periods.
Actions
ECDC is monitoring the measles situation through its epidemic intelligence activities. Data collected via epidemic intelligence supplement the monthly outputs of measles surveillance data from EpiPulse Cases, which are routinely submitted by 30 EU/EEA countries.
ECDC urges EU/EEA public health authorities to focus on the following areas:
- Close immunity gaps, achieve and maintain high vaccination coverage for measles-containing vaccines (>95% with the second dose). It is vital to ensure first and second dose vaccinations are administered on time, as per national schedules among infants and children. It is also important to identify and vaccinate eligible individuals (for example, non-immune adolescents and adults) in immunisation catch-up programmes (as recommended by local and national authorities).
- Strive towards high-quality surveillance and adequate public health capacity, especially for early detection, diagnosis, response and control of outbreaks.
- Increase the clinical awareness of health professionals, including reminding them of the importance of checking individuals' vaccination status ahead of travel.
- Healthcare professionals should be fully vaccinated.
- Promote vaccine acceptance and uptake by employing specific risk communication strategies and identifying drivers of suboptimal MMR vaccine acceptance and uptake to ensure that tailored interventions are implemented in response.
- Address barriers and engage with populations underserved by healthcare services. Systemic barriers that affect vaccine uptake in populations that are isolated and underserved by healthcare services need to be monitored and addressed with targeted strategies in order to reduce inequalities in vaccine uptake.
- In light of the upcoming summer holiday season, travellers should check their vaccination status and consult their general practitioner to ensure they are up-to-date with recommended immunisations prior to departure.
ECDC's latest advice on measles is available in the Threat Assessment Brief 'Measles on the rise in the EU/EEA: Considerations for a public health response', published in February 2024 and the conclusions remain valid. Additional information on the risk classification and ECDC recommendations can be found in this report.